[go: up one dir, main page]

CY1119831T1 - Αποτρεπτικα της καταχρησης σκευασματα φαρμακων - Google Patents

Αποτρεπτικα της καταχρησης σκευασματα φαρμακων

Info

Publication number
CY1119831T1
CY1119831T1 CY20171101337T CY171101337T CY1119831T1 CY 1119831 T1 CY1119831 T1 CY 1119831T1 CY 20171101337 T CY20171101337 T CY 20171101337T CY 171101337 T CY171101337 T CY 171101337T CY 1119831 T1 CY1119831 T1 CY 1119831T1
Authority
CY
Cyprus
Prior art keywords
drug
abuse
insoluble
water
composition
Prior art date
Application number
CY20171101337T
Other languages
English (en)
Inventor
Jane Hirsh
Alison B. Fleming
Roman V. Rariy
Alexander M. Klibanov
Original Assignee
Collegium Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34972336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119831(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Collegium Pharmaceutical, Inc. filed Critical Collegium Pharmaceutical, Inc.
Publication of CY1119831T1 publication Critical patent/CY1119831T1/el

Links

Classifications

    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
    • H04N21/40—Client devices specifically adapted for the reception of or interaction with content, e.g. set-top-box [STB]; Operations thereof
    • H04N21/41—Structure of client; Structure of client peripherals
    • H04N21/4104—Peripherals receiving signals from specially adapted client devices
    • H04N21/4126—The peripheral being portable, e.g. PDAs or mobile phones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F3/00—Input arrangements for transferring data to be processed into a form capable of being handled by the computer; Output arrangements for transferring data from processing unit to output unit, e.g. interface arrangements
    • G06F3/01—Input arrangements or combined input and output arrangements for interaction between user and computer
    • G06F3/048—Interaction techniques based on graphical user interfaces [GUI]
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F3/00—Input arrangements for transferring data to be processed into a form capable of being handled by the computer; Output arrangements for transferring data from processing unit to output unit, e.g. interface arrangements
    • G06F3/16—Sound input; Sound output
    • G06F3/167—Audio in a user interface, e.g. using voice commands for navigating, audio feedback
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q20/00—Payment architectures, schemes or protocols
    • G06Q20/08—Payment architectures
    • G06Q20/20—Point-of-sale [POS] network systems
    • G06Q20/209—Specified transaction journal output feature, e.g. printed receipt or voice output
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q20/00—Payment architectures, schemes or protocols
    • G06Q20/30—Payment architectures, schemes or protocols characterised by the use of specific devices or networks
    • G06Q20/32—Payment architectures, schemes or protocols characterised by the use of specific devices or networks using wireless devices
    • G06Q20/327—Short range or proximity payments by means of M-devices
    • G06Q20/3276—Short range or proximity payments by means of M-devices using a pictured code, e.g. barcode or QR-code, being read by the M-device
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q20/00—Payment architectures, schemes or protocols
    • G06Q20/30—Payment architectures, schemes or protocols characterised by the use of specific devices or networks
    • G06Q20/32—Payment architectures, schemes or protocols characterised by the use of specific devices or networks using wireless devices
    • G06Q20/327—Short range or proximity payments by means of M-devices
    • G06Q20/3278—RFID or NFC payments by means of M-devices
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q20/00—Payment architectures, schemes or protocols
    • G06Q20/38—Payment protocols; Details thereof
    • G06Q20/40—Authorisation, e.g. identification of payer or payee, verification of customer or shop credentials; Review and approval of payers, e.g. check credit lines or negative lists
    • G06Q20/401—Transaction verification
    • G06Q20/4014—Identity check for transactions
    • G—PHYSICS
    • G08—SIGNALLING
    • G08C—TRANSMISSION SYSTEMS FOR MEASURED VALUES, CONTROL OR SIMILAR SIGNALS
    • G08C19/00—Electric signal transmission systems
    • G—PHYSICS
    • G10—MUSICAL INSTRUMENTS; ACOUSTICS
    • G10L—SPEECH ANALYSIS TECHNIQUES OR SPEECH SYNTHESIS; SPEECH RECOGNITION; SPEECH OR VOICE PROCESSING TECHNIQUES; SPEECH OR AUDIO CODING OR DECODING
    • G10L15/00—Speech recognition
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
    • H04N21/20—Servers specifically adapted for the distribution of content, e.g. VOD servers; Operations thereof
    • H04N21/25—Management operations performed by the server for facilitating the content distribution or administrating data related to end-users or client devices, e.g. end-user or client device authentication, learning user preferences for recommending movies
    • H04N21/254—Management at additional data server, e.g. shopping server, rights management server
    • H04N21/2543—Billing, e.g. for subscription services
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
    • H04N21/20—Servers specifically adapted for the distribution of content, e.g. VOD servers; Operations thereof
    • H04N21/25—Management operations performed by the server for facilitating the content distribution or administrating data related to end-users or client devices, e.g. end-user or client device authentication, learning user preferences for recommending movies
    • H04N21/266—Channel or content management, e.g. generation and management of keys and entitlement messages in a conditional access system, merging a VOD unicast channel into a multicast channel
    • H04N21/2668—Creating a channel for a dedicated end-user group, e.g. insertion of targeted commercials based on end-user profiles
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
    • H04N21/40—Client devices specifically adapted for the reception of or interaction with content, e.g. set-top-box [STB]; Operations thereof
    • H04N21/41—Structure of client; Structure of client peripherals
    • H04N21/418—External card to be used in combination with the client device, e.g. for conditional access
    • H04N21/4185—External card to be used in combination with the client device, e.g. for conditional access for payment
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
    • H04N21/40—Client devices specifically adapted for the reception of or interaction with content, e.g. set-top-box [STB]; Operations thereof
    • H04N21/43—Processing of content or additional data, e.g. demultiplexing additional data from a digital video stream; Elementary client operations, e.g. monitoring of home network or synchronising decoder's clock; Client middleware
    • H04N21/436—Interfacing a local distribution network, e.g. communicating with another STB or one or more peripheral devices inside the home
    • H04N21/4363—Adapting the video stream to a specific local network, e.g. a Bluetooth® network
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
    • H04N21/40—Client devices specifically adapted for the reception of or interaction with content, e.g. set-top-box [STB]; Operations thereof
    • H04N21/45—Management operations performed by the client for facilitating the reception of or the interaction with the content or administrating data related to the end-user or to the client device itself, e.g. learning user preferences for recommending movies, resolving scheduling conflicts
    • H04N21/458—Scheduling content for creating a personalised stream, e.g. by combining a locally stored advertisement with an incoming stream; Updating operations, e.g. for OS modules ; time-related management operations
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
    • H04N21/40—Client devices specifically adapted for the reception of or interaction with content, e.g. set-top-box [STB]; Operations thereof
    • H04N21/47—End-user applications
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N5/00—Details of television systems
    • H04N5/44—Receiver circuitry for the reception of television signals according to analogue transmission standards
    • H04N5/60—Receiver circuitry for the reception of television signals according to analogue transmission standards for the sound signals
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W12/00—Security arrangements; Authentication; Protecting privacy or anonymity
    • H04W12/50—Secure pairing of devices
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W12/00—Security arrangements; Authentication; Protecting privacy or anonymity
    • H04W12/60—Context-dependent security
    • H04W12/69—Identity-dependent
    • H04W12/77—Graphical identity
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/80—Services using short range communication, e.g. near-field communication [NFC], radio-frequency identification [RFID] or low energy communication

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Business, Economics & Management (AREA)
  • Signal Processing (AREA)
  • Theoretical Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Multimedia (AREA)
  • General Physics & Mathematics (AREA)
  • Accounting & Taxation (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • General Business, Economics & Management (AREA)
  • Strategic Management (AREA)
  • Computer Security & Cryptography (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Databases & Information Systems (AREA)
  • General Engineering & Computer Science (AREA)
  • Human Computer Interaction (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Finance (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Audiology, Speech & Language Pathology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)

Abstract

Αναπτύχθηκε μια αποτρεπτική της κατάχρησης φαρμακευτική σύνθεση προς μείωση της πιθανότητας ακατάλληλης χορήγησης φαρμάκων, ειδικώς φαρμάκων όπως οπιοειδή. Στην προτιμώμενη ενσωμάτωση, το φάρμακο τροποποιείται για να αυξηθεί η λιποφιλία του διά του σχηματισμού ενός άλατος μεταξύ του φαρμάκου και ενός ή περισσότερων λιπαρών οξέων όπου η συγκέντρωση του ενός ή περισσότερων λιπαρών οξέων είναι μία έως 15 φορές η γραμμομοριακή ποσότητα του ενεργού παράγοντα, κατά προτίμηση δύο έως δέκα φορές η γραμμομοριακή ποσότητα του ενεργού παράγοντα. Σε μια ενσωμάτωση το τροποποιημένο φάρμακο διασπείρεται ομοιογενώς εντός μικροσωματιδίων αποτελούμενων από ένα υλικό που είτε είναι βραδέως διαλυτό είτε μη διαλυτό σε ύδωρ. Σε μερικές ενσωματώσεις τα περιέχοντα φάρμακο μικροσωματίδια ή σωματίδια φαρμάκου επικαλύπτονται με μία ή περισσότερες στιβάδες επικάλυψης, όπου τουλάχιστον μία επικάλυψη είναι αδιάλυτη σε ύδωρ και κατά προτίμηση αδιάλυτη σε οργανικό διαλύτη. Η αποτρεπτική της κατάχρησης σύνθεση παρεμποδίζει την άμεση απελευθέρωση ενός σημαντικού μέρους του φαρμάκου, ακόμη και όταν η φυσική ακεραιότητα του σκευάσματος τίθεται σε κίνδυνο (για παράδειγμα, με τεμαχισμό με μια λεπτίδα ή σύνθλιψη) και το προκύπτον υλικό τοποθετείται σε ύδωρ, εισπνέεται μέσω της μύτης, ή καταπίνεται. Εντούτοις, όταν χορηγείται όπως υποδεικνύεται, το φάρμακο απελευθερώνεται βραδέως από τη σύνθεση καθώς η σύνθεση διασπάται ή διαλύεται βαθμιαία εντός του γαστροεντερικού σωλήνα με έναν συνδυασμό ενζυμικής αποδόμησης, επιφανειοδραστικής δράσης χολικών οξέων, και μηχανικής διάβρωσης.
CY20171101337T 2004-06-12 2017-12-20 Αποτρεπτικα της καταχρησης σκευασματα φαρμακων CY1119831T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57919104P 2004-06-12 2004-06-12
PCT/US2005/020588 WO2005123039A1 (en) 2004-06-12 2005-06-10 Abuse-deterrent drug formulations

Publications (1)

Publication Number Publication Date
CY1119831T1 true CY1119831T1 (el) 2018-06-27

Family

ID=34972336

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101337T CY1119831T1 (el) 2004-06-12 2017-12-20 Αποτρεπτικα της καταχρησης σκευασματα φαρμακων

Country Status (12)

Country Link
US (12) US7771707B2 (el)
EP (2) EP3326617A1 (el)
CA (2) CA2916869A1 (el)
CY (1) CY1119831T1 (el)
DK (1) DK1765292T3 (el)
ES (1) ES2653568T3 (el)
HU (1) HUE037643T2 (el)
LT (1) LT1765292T (el)
PL (1) PL1765292T3 (el)
PT (1) PT1765292T (el)
SI (1) SI1765292T1 (el)
WO (1) WO2005123039A1 (el)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
PT1492531E (pt) 2002-04-09 2008-12-10 Flamel Tech Sa Formulação farmacêutica oral sob a forma de suspensão aquosa de microcápsulas que permite a libertação modificada de amoxicilina
DE60325709D1 (de) 2002-04-09 2009-02-26 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
US8557291B2 (en) * 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
JP4694207B2 (ja) * 2002-07-05 2011-06-08 コルジウム ファーマシューティカル， インコーポレイテッド オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物
US8840928B2 (en) 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
ES2360102T3 (es) 2003-03-26 2011-05-31 Egalet A/S Sistema para la liberación controlada de morfina.
PT1765292T (pt) * 2004-06-12 2017-12-29 Collegium Pharmaceutical Inc Formulações de fármacos dissuasoras de abuso
WO2006133733A1 (en) * 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
US9125833B2 (en) * 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
US8329744B2 (en) * 2005-11-02 2012-12-11 Relmada Therapeutics, Inc. Methods of preventing the serotonin syndrome and compositions for use thereof
WO2007056142A2 (en) * 2005-11-02 2007-05-18 Theraquest Biosciences, Llc Methods of preventing the serotonin syndrome and compositions for use therefor
WO2007087452A2 (en) * 2006-01-27 2007-08-02 Theraquest Biosciences, Llc Abuse resistant and extended release formulations and method of use thereof
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
ZA200807571B (en) * 2006-03-01 2009-08-26 Ethypharm Sa Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
WO2008070149A2 (en) * 2006-12-05 2008-06-12 Neurogesx, Inc. Prodrugs and methods of making and using the same
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
CA2689434C (en) * 2007-06-04 2017-09-26 Shear/Kershman Laboratories, Inc. Tamper resistant lipid-based oral dosage form for opioid agonists
EP2187873B1 (en) 2007-08-13 2018-07-25 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
US20110268798A1 (en) * 2009-01-16 2011-11-03 Add Advanced Drug Delivery Technologies Ltd Orally disntegrating tablets for the treatment of pain
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
GB201006200D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
GB201008049D0 (en) 2010-05-13 2010-06-30 Ayanda As Composition
US20120065092A1 (en) * 2010-09-14 2012-03-15 Wai Hobert Fusion analyte cytometric bead assay, and systems and kits for performing the same
WO2012112952A1 (en) 2011-02-17 2012-08-23 QRxPharma Ltd. Technology for preventing abuse of solid dosage forms
US9730637B2 (en) * 2011-08-19 2017-08-15 The Regents Of The University Of California Layered particles for retrieving DNA released from cells from a gastrointestinal tract sample and methods for making and using them
WO2013090439A1 (en) * 2011-12-12 2013-06-20 Orbis Biosciences, Inc. Sustained release particle formulations of guaifenesin
TW201330851A (zh) * 2012-01-20 2013-08-01 Renascence Therapeutics Ltd 用於鼻內施用唑吡坦（ｚｏｌｐｉｄｅｍ）的治療組合物
KR20150059167A (ko) 2012-07-06 2015-05-29 에갈렛 리미티드 제어된 방출을 위한 남용 제지 약학적 조성물
US20140275038A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US10078986B2 (en) 2015-09-15 2018-09-18 Sharp Life Science (Eu) Limited Active matrix device and method of driving
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
EP3246000A1 (en) * 2016-05-18 2017-11-22 Capsugel Belgium NV Separable capsule for sprinkling applications
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10532385B2 (en) 2016-06-29 2020-01-14 Disposerx, Inc. Disposal of medicaments
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
WO2019064026A1 (en) * 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
EP3704123A1 (en) * 2017-10-30 2020-09-09 Theracaine LLC Hydrophobic acid addition salts and pharmaceutical formulations thereof
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
GB201904771D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions

Family Cites Families (331)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US199530A (en) * 1878-01-22 Improvement in injectors
US297617A (en) * 1884-04-29 Alfeed s
US142943A (en) * 1873-09-16 Improvement in car-couplings
US1162778A (en) * 1915-04-02 1915-12-07 Home Ironing Board Company Ironing-board.
US1349326A (en) 1920-01-20 1920-08-10 Charles T Davis Poison-tablet
US2404319A (en) 1941-06-28 1946-07-16 Wm S Merrell Co Butanolamine salts of theophylline
US3402240A (en) 1957-06-25 1968-09-17 Pfizer & Co C Medicinal tablet and process of making same
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
US3015128A (en) * 1960-08-18 1962-01-02 Southwest Res Inst Encapsulating apparatus
NL271831A (el) 1960-11-29
US3146167A (en) 1961-10-05 1964-08-25 Smith Kline French Lab Method of preparing sustained release pellets and products thereof
US3260646A (en) 1962-10-19 1966-07-12 Ferring Ab Medication with mechanism to prevent overdosage
US3172816A (en) 1963-01-28 1965-03-09 Smith Kline French Lab Method of increasing the oil solubility of compounds and products thereof
US3336200A (en) * 1963-05-28 1967-08-15 Warner Lambert Pharmaceutical Tablet structure
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US4132753A (en) 1965-02-12 1979-01-02 American Cyanamid Company Process for preparing oral sustained release granules
NL6714885A (el) 1967-11-02 1969-05-06
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3773955A (en) 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3879555A (en) 1970-11-16 1975-04-22 Bristol Myers Co Method of treating drug addicts
GB1405088A (en) 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
US3965256A (en) 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3980766A (en) 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3916889A (en) 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
US3966940A (en) 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
DE2426812A1 (de) * 1974-06-04 1976-01-02 Klinge Co Chem Pharm Fab Verfahren zur herstellung von granulaten
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
JPS51151190A (en) 1975-06-19 1976-12-25 Sugiyama Sangyo Kagaku Kenkyusho Testing paper for measurement of oil and fat peroxide value
DE2530563C2 (de) * 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4175119A (en) 1978-01-11 1979-11-20 Porter Garry L Composition and method to prevent accidental and intentional overdosage with psychoactive drugs
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
NO154582C (no) 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4293539A (en) 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
IE49324B1 (en) 1979-12-19 1985-09-18 Euro Celtique Sa Controlled release compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
DE3024416C2 (de) 1980-06-28 1982-04-15 Gödecke AG, 1000 Berlin Verfahren zur Herstellung von Arzneimitteln mit retardierter Wirkstoff-Freisetzung
US4424205A (en) 1982-03-18 1984-01-03 The Procter & Gamble Company Hydroxyphenylacetamides having analgesic and anti-irritant activity
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4443428A (en) 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US4459278A (en) 1983-03-07 1984-07-10 Clear Lake Development Group Composition and method of immobilizing emetics and method of treating human beings with emetics
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
DK149776C (da) 1984-01-06 1987-04-21 Orion Yhtymae Oy Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen
US4681897A (en) 1984-01-16 1987-07-21 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
GB2162061B (en) 1984-05-03 1988-11-16 Bibhuti B Bardhan Controlled time release therapeutic composition having means for counteracting overdosage
US4675140A (en) 1984-05-18 1987-06-23 Washington University Technology Associates Method for coating particles or liquid droplets
US4629623A (en) 1984-06-11 1986-12-16 Biomatrix, Inc. Hyaluronate-poly (ethylene oxide) compositions and cosmetic formulations thereof
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
EP0179583A1 (en) 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
US4610870A (en) 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8430346D0 (en) 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4569937A (en) * 1985-02-11 1986-02-11 E. I. Du Pont De Nemours And Company Analgesic mixture of oxycodone and ibuprofen
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4666705A (en) 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
ES2058111T3 (es) 1986-06-10 1994-11-01 Euro Celtique Sa Composicion de liberacion controlada de dihidrocodeina.
US4713243A (en) 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
US4785000A (en) 1986-06-18 1988-11-15 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4737151A (en) 1986-07-25 1988-04-12 Clement John G Syringe injector
US4710384A (en) 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
JPH0819004B2 (ja) 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
GB8727504D0 (en) 1987-11-24 1987-12-23 Glaxo Group Ltd Chemical compositions
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
US5139790A (en) 1988-10-14 1992-08-18 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US4939149A (en) 1988-10-24 1990-07-03 The United States Of America As Represented By The Department Of Health And Human Services Resiniferatoxin and analogues thereof to cause sensory afferent C-fiber and thermoregulatory desensitization
US5026556A (en) 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
IL92343A0 (en) 1988-12-20 1990-07-26 Gist Brocades Nv Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them
US5403868A (en) 1988-12-23 1995-04-04 Sandoz Ltd. Capsaicin derivatives
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5330766A (en) 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5059600A (en) 1989-03-31 1991-10-22 Yale University Treating habit disorders
US5114942A (en) 1989-03-31 1992-05-19 Yale University Treating habit disorders
US4992277A (en) 1989-08-25 1991-02-12 Schering Corporation Immediate release diltiazem formulation
EP0418596A3 (en) 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
DE3937118A1 (de) 1989-11-03 1991-05-08 Schering Ag Nichtionische roentgenkontrastmittel mit hohem jodgehalt
US5232685A (en) 1989-11-03 1993-08-03 Schering Aktiengesellschaft Nonionic x-ray contrast medium with high iodine content
GB8926612D0 (en) 1989-11-24 1990-01-17 Erba Farmitalia Pharmaceutical compositions
US5240711A (en) 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
IT1237904B (it) 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
WO1991016044A1 (fr) 1990-04-24 1991-10-31 Teijin Limited Emplatre
FR2661324B1 (fr) 1990-04-25 1994-09-16 Didier Bernardin Presentoir d'objets en file.
US5679650A (en) 1993-11-24 1997-10-21 Fukunaga; Atsuo F. Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5246698A (en) 1990-07-09 1993-09-21 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
US6096722A (en) 1990-08-14 2000-08-01 Isis Pharmaceuticals Inc. Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
TW225536B (el) * 1990-08-23 1994-06-21 Ciba Geigy Ag
US5113585A (en) 1990-09-28 1992-05-19 The Gillette Company Shaving system
US5300302A (en) 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
FR2669336B1 (fr) 1990-11-20 1993-01-22 Adir Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5273758A (en) 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
EP0623155A4 (en) 1991-09-18 1995-01-11 Transcontinental Marketing Gro SINGLE-LAYER PROTECTIVE COATING SYSTEM FOR A SURFACE.
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5354863A (en) 1992-01-21 1994-10-11 G. D. Searle & Co. Opioid agonist compounds
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU658271B2 (en) 1992-03-26 1995-04-06 Tanabe Seiyaku Co., Ltd. Butadiene derivatives and process for preparing the same
ATE404201T1 (de) 1992-06-22 2008-08-15 Univ California Glycinrezeptorantagonisten und ihre verwendung
SI9200139A (en) 1992-07-08 1994-03-31 Lek Tovarna Farmacevtskih New inclusion complex of clavulanic acid with hydrophylyc and hydropholyc beta-cyclodextrin derivates for production of them
US5232934A (en) 1992-07-17 1993-08-03 Warner-Lambert Co. Method for the treatment of psychomotor stimulant addiction
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
SK281042B6 (sk) 1992-09-18 2000-11-07 Yamanouchi Pharmaceutical Co., Ltd Prípravok hydrogélového typu s ustáleným uvoľňovaním
US5472943A (en) 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
ES2180548T3 (es) 1992-10-16 2003-02-16 Nippon Shinyaku Co Ltd Metodo de obtencion de matrices de cera.
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
GB9226392D0 (en) 1992-12-18 1993-02-10 Cpc International Inc Gelling agent
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
CA2115792C (en) 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
JPH08508472A (ja) * 1993-03-26 1996-09-10 ダブリュー．エイチ．エム． マーカス フランシスカス ジヒドロエルゴタミン、アポモルヒネ及びモルヒネを鼻腔内へ投与するための薬剤
US5656291A (en) * 1994-03-16 1997-08-12 Pharmacia & Upjohn Aktiebolag Controlled release preparation
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US6312704B1 (en) 1993-09-30 2001-11-06 Gattefosse, S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
HU218673B (hu) 1993-10-07 2000-10-28 Euroceltique S.A. Opioid analgetikumot tartalmazó elnyújtott hatóanyag-felszabadítású orális gyógyszerkészítmény és eljárás előállítására
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
WO1995018602A1 (en) 1994-01-11 1995-07-13 Alkermes Controlled Therapeutics, Inc. ORAL DOSAGE FORM OF DESMOPRESSIN (dDAVP)
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
DE4413350A1 (de) 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
US5411745A (en) 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5529787A (en) 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US5914131A (en) 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
WO1996005884A1 (en) 1994-08-22 1996-02-29 Iomed, Inc. Iontophoretic delivery device with integral hydrating means
US5635159A (en) 1994-08-26 1997-06-03 Abbott Laboratories Aerosol drug formulations containing polyglycolyzed glycerides
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5575993A (en) 1994-08-31 1996-11-19 Buckman Laboratories International, Inc. Ionene polymers containing biologically-active anions
US6491945B1 (en) 1994-09-16 2002-12-10 Alza Corporation Hydrocodone therapy
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5756123A (en) 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
IL116674A (en) 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5545628A (en) 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5695781A (en) 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US6348469B1 (en) 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5643992A (en) 1995-06-02 1997-07-01 Minnesota Mining And Manufacturing Company Coating additives for water-based formulations
US5762963A (en) 1995-06-07 1998-06-09 Emory University Method and compositions for controlling oral and pharyngeal pain using capsaicinoids
EP1452622A3 (en) * 1995-08-23 2004-09-29 Asahi Glass Ceramics Co., Ltd. Target and process for its production, and method for forming a film having a high refractive index
US5811126A (en) 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
AUPN603895A0 (en) * 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
DE19607395C2 (de) * 1996-02-28 2002-11-21 Lohmann Therapie Syst Lts Salze aus einem kationischen narkotischen Analgetikum mit einem anionischen nichtnarkotischen Analgetikum, Verfahren zu deren Herstellung und die diese Salze enthaltenden pharmazeutischen Präparate
DK0914097T3 (da) 1996-03-12 2002-04-29 Alza Corp Sammensætning og doseringsform omfattende opioid antagonist
US5766623A (en) 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
DE69723248T2 (de) 1996-04-10 2004-05-27 Warner-Lambert Co. Llc Vergällungsstoffe für sympathomimetische aminsalze
AU3404997A (en) 1996-05-31 1998-01-05 Euro-Celtique S.A. Sustained release oxycodone formulations with no fed/fast effect
US6440464B1 (en) 1996-06-10 2002-08-27 Viva Life Science Nutritive composition for cardiovascular health containing fish oil, garlic, rutin, capsaicin, selenium, vitamins and juice concentrates
ATE427124T1 (de) 1996-06-26 2009-04-15 Univ Texas Heiss-geschmolzene extrudierbare pharmazeutische formulierung
JP2000512649A (ja) * 1996-06-27 2000-09-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 徐放性スフェンタニル組成物
AU712546B2 (en) 1996-07-11 1999-11-11 Farmarc Nederland Bv Inclusion complex containing indole selective serotonin agonist
US5914129A (en) 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
US20010003588A1 (en) 1996-09-12 2001-06-14 Smithkline Beecham Corporation Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride
AU4414497A (en) 1996-09-13 1998-04-02 University Technology Corporation Biocompatible cationic detergents and uses therefor
AU4717997A (en) 1996-10-28 1998-05-22 Farmarc Nederland Bv Inclusion complexes of beta-2-andrenergics for oral mucosal delivery
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6124282A (en) 1997-05-22 2000-09-26 Sellers; Edward M. Drug formulations
JP2002514221A (ja) 1997-05-27 2002-05-14 アルゴス ファーマシューティカル コーポレーション カプサイシノイド及びその強化薬を含有する鎮痛薬組成物
US6153621A (en) 1997-06-23 2000-11-28 The University Of Kentucky Research Foundation Combined antagonist compositions
WO1999001111A1 (en) 1997-07-02 1999-01-14 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US5891919A (en) 1997-09-19 1999-04-06 Burlington Bio-Medical & Scientific Corp. Denatonium capsaicinate and methods of producing the same
CA2302275C (en) 1997-09-19 2009-12-08 Shire Laboratories, Inc. Solid solution beadlet
US6294194B1 (en) 1997-10-14 2001-09-25 Boehringer Ingelheim Pharmaceuticals, Inc. Method for extraction and reaction using supercritical fluids
US6066339A (en) 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
DE69805001T2 (de) 1997-12-05 2002-08-22 Alza Corp., Palo Alto Osmotische darreichungsform mit zwei mantelschichten
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
RU2241458C2 (ru) 1997-12-22 2004-12-10 Эро-Селтик, С.А. Комбинации агонист/антагонист опиоида
US6228863B1 (en) 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
WO1999033490A1 (fr) * 1997-12-26 1999-07-08 Yamanouchi Pharmaceutical Co., Ltd. Compositions medicinales a liberation prolongee
US6251430B1 (en) 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
FR2775188B1 (fr) 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
DE1003485T1 (de) 1998-06-11 2000-11-02 Em Industries, Inc. Mikroosmotisches gesteuertes arzneistoffabgabesysteme
GB9814411D0 (en) 1998-07-03 1998-09-02 Mw Encap Limited Capsule sealing system
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
FR2787715B1 (fr) 1998-12-23 2002-05-10 Synthelabo Composition pharmaceutique comprenant un compose hypnotique ou un de ses sels pharmaceutiquement acceptables
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
DE60023465T2 (de) 1999-03-24 2006-07-20 R.P. Scherer Technologies, Inc., Las Vegas Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
US20030170181A1 (en) 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
CA2273808A1 (en) 1999-06-09 2000-12-09 Jaromir Friedrich Method and apparatus for granulating bee wax
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
AU6381300A (en) 1999-07-29 2001-02-19 Roxane Laboratories, Inc. Opioid sustained-released formulation
DE19940740A1 (de) * 1999-08-31 2001-03-01 Gruenenthal Gmbh Pharmazeutische Salze
US6177567B1 (en) 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
AR031682A1 (es) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US20020131988A1 (en) 1999-12-16 2002-09-19 Foster Todd P. Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
US6352721B1 (en) 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US6491949B2 (en) 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
DK2092936T3 (da) * 2000-02-08 2013-06-17 Euro Celtique Sa Orale opioid-agonist-formuleringer sikret mod forfalskning
ES2253364T3 (es) 2000-03-28 2006-06-01 Farmarc Nederland B.V. Complejos de inclusion de alprazolam y sus composiciones farmaceuticas.
US6468559B1 (en) 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
CN1469707A (zh) 2000-08-10 2004-01-21 �¶���˹ҩƷ��˾ 改进的疏水性药物的固体药物剂量制剂
ATE449596T1 (de) 2000-08-15 2009-12-15 Univ Illinois Verfahren zur herstellung von mikropartikeln
EP2263658A1 (en) 2000-10-30 2010-12-22 Euro-Celtique S.A. Controlled release hydrocodone formulations
US6559159B2 (en) 2001-02-01 2003-05-06 Research Triangle Institute Kappa opioid receptor ligands
MXPA03008292A (es) 2001-03-13 2003-12-11 Penwest Pharmaceuticals Co Formas de dosificacion cronoterapeuticas que contienen glucocorticosteroides.
US6780424B2 (en) 2001-03-30 2004-08-24 Charles David Claude Controlled morphologies in polymer drug for release of drugs from polymer films
US20020187192A1 (en) 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CA2778114A1 (en) 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20030035839A1 (en) 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
US20030064122A1 (en) 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
WO2003002100A1 (en) 2001-06-26 2003-01-09 Farrell John J Tamper-proof narcotic delivery system
US20030021841A1 (en) 2001-07-02 2003-01-30 Matharu Amol Singh Pharmaceutical composition
WO2003004033A1 (en) 2001-07-06 2003-01-16 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US20150031718A1 (en) 2001-08-06 2015-01-29 Purdue Pharma L.P. Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7141250B2 (en) * 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
WO2003015531A2 (en) 2001-08-06 2003-02-27 Thomas Gruber Pharmaceutical formulation containing dye
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
WO2003020241A2 (en) 2001-09-05 2003-03-13 Vectura Limited Functional powders for oral delivery
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20030059397A1 (en) 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
US20030091635A1 (en) 2001-09-26 2003-05-15 Baichwal Anand R. Opioid formulations having reduced potential for abuse
JP2005035888A (ja) 2001-10-25 2005-02-10 Ta Stevia Co Ltd アナフィラキシー型アレルギー症状改善物質およびその製造方法
US20040126428A1 (en) 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
WO2003039561A1 (en) 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
WO2003055468A1 (en) 2001-12-21 2003-07-10 Shire Laboratories Inc. Oral capsule formulation with increased physical stability
TW573259B (en) 2001-12-28 2004-01-21 Admtek Inc LIFM algorithm for security association database lookup in IPSec application
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
ATE419830T1 (de) 2002-04-29 2009-01-15 Alza Corp Methoden und darreichungsformen zur kontrollierten freisetzung von oxykodon
US20050106249A1 (en) 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
US20060034872A1 (en) 2002-04-29 2006-02-16 Woolf Clifford J Compositions and methods for preventing abuse of orally administered medications
US7157100B2 (en) 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US7288244B2 (en) * 2002-07-02 2007-10-30 Nv Thermocore Medical Systems Sa Determining vulnerable plaque in blood vessels
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
JP4694207B2 (ja) * 2002-07-05 2011-06-08 コルジウム ファーマシューティカル， インコーポレイテッド オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物
US8840928B2 (en) 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
CA2498798A1 (en) 2002-09-20 2004-04-01 Alpharma, Inc. Sustained-release opioid formulations and methods of use
SI1551372T1 (en) 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
CA2499994C (en) * 2002-09-23 2012-07-10 Verion, Inc. Abuse-resistant pharmaceutical compositions
US20040062778A1 (en) 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
DE10250084A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20050186139A1 (en) 2002-10-25 2005-08-25 Gruenenthal Gmbh Abuse-proofed dosage form
US7192966B2 (en) 2002-11-15 2007-03-20 Branded Products For The Future Pharmaceutical composition
US20040224020A1 (en) 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US7524515B2 (en) 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
EP1599186B1 (en) 2003-02-24 2013-04-10 Pharmaceutical Productions Inc. Transmucosal drug delivery system
ES2360102T3 (es) 2003-03-26 2011-05-31 Egalet A/S Sistema para la liberación controlada de morfina.
JP4790597B2 (ja) 2003-04-24 2011-10-12 ヤゴテック アーゲー 規定されたコア幾何学的配置を有する遅延放出錠
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
US20040241234A1 (en) 2003-06-02 2004-12-02 Alpharma, Inc. Controlled release press-coated formulations of water-soluble active agents
US20060165790A1 (en) 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004020220A1 (de) 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
NZ545921A (en) 2003-09-19 2009-09-25 Penwest Pharmaceuticals Co Delayed released dosage forms
JP2007519608A (ja) 2003-09-19 2007-07-19 ペンウェスト ファーマシューティカルズ カンパニー 時間治療用剤形
EP1680094A1 (en) 2003-09-26 2006-07-19 Alza Corporation Controlled release formulations of opioid and nonopioid analgesics
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
JP2007513139A (ja) 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 安定性の改善した多粒子組成物
US7867511B2 (en) 2004-01-23 2011-01-11 Travanti Pharma Inc. Abuse potential reduction in abusable substance dosage form
US20050181050A1 (en) 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
PT1765292T (pt) 2004-06-12 2017-12-29 Collegium Pharmaceutical Inc Formulações de fármacos dissuasoras de abuso
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032103A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US20060018837A1 (en) 2004-07-26 2006-01-26 Victory Pharma, Inc. Pharmaceutical compositions and methods for the prevention of drug misuse
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
GB0421149D0 (en) 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
WO2006036984A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Stand-alone film and methods for making the same
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
KR20090037930A (ko) 2006-07-11 2009-04-16 뮤추얼 파마슈티컬 컴퍼니 아이엔씨. 조절 방출 제형
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US20080176955A1 (en) 2007-01-16 2008-07-24 Victory Pharma, Inc. Combined administration of benzonatate and guaifenesin
US20150164835A1 (en) 2007-05-22 2015-06-18 Pisgah Laboratories, Inc. Opioid Salts with Release Properties and Characteristics Useful for Abuse Deterrent Drug Product Formulations
AU2008347158B8 (en) 2007-12-06 2013-08-22 Durect Corporation Oral pharmaceutical dosage forms
US8362029B2 (en) 2008-12-31 2013-01-29 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
PT2826467T (pt) 2010-12-22 2017-10-25 Purdue Pharma Lp Formas envolvidas de dosamento de libertação controlada resistentes à adulteração
JP6016810B2 (ja) 2011-01-11 2016-10-26 シグネーチャー セラピューティクス, インク.Signature Therapeutics, Inc. 酵素切断可能なオキシコドンプロドラッグを含んでなる組成物
US10420729B2 (en) 2013-03-15 2019-09-24 R.P. Scherer Technologies, Llc Abuse resistant capsule
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations

Also Published As

Publication number Publication date
HUE037643T2 (hu) 2018-09-28
CA2569958C (en) 2016-03-22
US20160074326A1 (en) 2016-03-17
PL1765292T3 (pl) 2018-03-30
US8449909B2 (en) 2013-05-28
DK1765292T3 (en) 2018-01-02
US20140121232A1 (en) 2014-05-01
SI1765292T1 (en) 2018-04-30
US20200345723A1 (en) 2020-11-05
US20100260834A1 (en) 2010-10-14
US20170360710A1 (en) 2017-12-21
EP1765292B1 (en) 2017-10-04
US20130310413A1 (en) 2013-11-21
LT1765292T (lt) 2018-01-10
US20200093819A1 (en) 2020-03-26
CA2916869A1 (en) 2005-12-29
CA2569958A1 (en) 2005-12-29
US8758813B2 (en) 2014-06-24
PT1765292T (pt) 2017-12-29
US9592200B2 (en) 2017-03-14
US9763883B2 (en) 2017-09-19
US10525053B2 (en) 2020-01-07
US20170182032A1 (en) 2017-06-29
US20200093820A1 (en) 2020-03-26
US7771707B2 (en) 2010-08-10
EP3326617A1 (en) 2018-05-30
US20200345722A1 (en) 2020-11-05
US20050281748A1 (en) 2005-12-22
EP1765292A1 (en) 2007-03-28
US20180028529A1 (en) 2018-02-01
US10525052B2 (en) 2020-01-07
WO2005123039A1 (en) 2005-12-29
ES2653568T3 (es) 2018-02-07

Similar Documents

Publication Publication Date Title
CY1119831T1 (el) Αποτρεπτικα της καταχρησης σκευασματα φαρμακων
Jacob et al. An updated overview of the emerging role of patch and film-based buccal delivery systems
Caon et al. Enhancing the buccal mucosal delivery of peptide and protein therapeutics
Xu et al. Genipin-crosslinked catechol-chitosan mucoadhesive hydrogels for buccal drug delivery
US9572773B2 (en) Layered drug delivery device
ES2663777T3 (es) Dispositivos de administración mucosa multidireccionales y métodos de uso
Gupta et al. Recent trends in oral drug delivery: a review
JP4619894B2 (ja) 粘膜表面への、薬剤化合物の送達に適する薬剤キャリアデバイス
Guggi et al. Systemic peptide delivery via the stomach: in vivo evaluation of an oral dosage form for salmon calcitonin
AR048250A1 (es) Productos de pelicula que tienen propiedades de disgregacion controlada
Khan et al. Development of novel pH-sensitive nanoparticle-based transdermal patch for management of rheumatoid arthritis
Ribeiro et al. Advances in Hybrid Polymer‐Based Materials for Sustained Drug Release
EP1968638B1 (en) Controlled release gels
Jain et al. Lectin conjugated gastroretentive multiparticulate delivery system of clarithromycin for the effective treatment of Helicobacter pylori
PT1210934E (pt) Preparação de transportador farmacêutico aplicável a superfícies de mucosas
DE60131991D1 (de) Nanopartikuläre zusammensetzungen in form festen darreichungen
Alawdi et al. Mucoadhesive drug delivery systems: A review of recent developments
KR20240036586A (ko) 선형 다당류-기반 필름 생성물
TW200502008A (en) Patches for mucosa of oral cavity containing fentanyl
DE69932201D1 (de) Emulsionen für in-situ Arzneistoffabgabesysteme
CO5690532A2 (es) Formas de dosificacion farmaceutica de liberacion extendida
CN101820919A (zh) 用于局部药物输送的可注射聚合物-脂质共混物
Suksaeree et al. Formulation, characterization, and in vitro evaluation of transdermal patches for inhibiting crystallization of mefenamic acid
Hansen et al. Operationalization and application of “early warning signs” to screen nanomaterials for harmful properties
AR023138A1 (es) Composicion para gomas de mascar medicadas, proceso de fabricacion y tabletas obtenidas con dicho proceso